Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Cost of Revenue (2019 - 2025)

Coherus Oncology's Cost of Revenue history spans 7 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 105.4% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $13.8 million, up 120.02%, while the annual FY2025 figure was $13.8 million, 58.29% up from the prior year.
  • Cost of Revenue for Q4 2025 was $4.0 million at Coherus Oncology, up from $3.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $84.6 million in Q4 2023 and bottomed at -$75.0 million in Q4 2024.
  • The 5-year median for Cost of Revenue is $10.3 million (2022), against an average of $11.6 million.
  • The largest annual shift saw Cost of Revenue soared 495.46% in 2023 before it tumbled 188.65% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $12.1 million in 2021, then rose by 17.33% to $14.2 million in 2022, then skyrocketed by 495.46% to $84.6 million in 2023, then tumbled by 188.65% to -$75.0 million in 2024, then skyrocketed by 105.4% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Cost of Revenue are $4.0 million (Q4 2025), $3.7 million (Q3 2025), and $3.4 million (Q2 2025).